朝着用于光动力疗法的二核铼(Ⅰ)-钌(Ⅱ)配合物的方向迈进。
Towards Ruthenium(II)-Rhenium(I) Binuclear Complexes as Photosensitizers for Photodynamic Therapy.
发表日期：2023 Aug 01
作者：
Youchao Wang, Patrick S Felder, Pierre Mesdom, Olivier Blacque, Thomas L Mindt, Kevin Cariou, Gilles Gasser
来源：
Cellular & Molecular Immunology
摘要：
寻找新型基于金属的光敏剂（photosensitizers，简称PSs）用于抗癌光动力疗法（photodynamic therapy，简称PDT）是一个快速发展的研究领域。鉴于多金属配合物作为PDT PSs具有很高的潜力，本研究旨在将一种已知的铼（Re）一车烯基配合物的光物理性质与一种钌（Ru）二聚吡啶配合物相结合，以制备一种能够作为抗癌PDT PSs的钌铼双核配合物。在这里，我们介绍了这种体系的合成和表征，并讨论了其在水溶液中的稳定性。此外，我们制备的其中一种定位于线粒体的配合物发现对两种癌细胞具有一定的选择性：人肺癌A549和人结直肠腺癌HT29，与非癌变视网膜色素上皮RPE1细胞相比，有有趣的光指数（photo-index，简称PI）值分别为135.1和256.4，对应的数值分别为22.4。© 2023年 Wiley-VCH GmbH。
The search for new metal-based photosensitizers (PSs) for anticancer photodynamic therapy (PDT) is a fast-developing field of research. Knowing that polymetallic complexes bear a high potential as PDT PSs, in this study, we aimed at combining the known photophysical properties of a rhenium(I) tricarbonyl complex and a ruthenium(II) polypyridyl complex to prepare a ruthenium-rhenium binuclear complex that could act as a PS for anticancer PDT. Herein, we present the synthesis and characterization of such a system and discuss its stability in aqueous solution. In addition, one of our complexes prepared, which localized in mitochondria, was found to have some degree of selectivity towards two types of cancerous cells: human lung carcinoma A549 and human colon colorectal adenocarcinoma HT29, with interesting photo-index (PI) values of 135.1 and 256.4, respectively, compared to noncancerous retinal pigment epithelium RPE1 cells (22.4).© 2023 Wiley-VCH GmbH.